MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. The company trades on NCM exchange. The company headquarter is located in Zug, Switzerland. The company was established in the 2021.

TickerMLTX
Long NameMoonLake Immunotherapeutics
Short NameMoonLake Immunotherapeutics